Drawing on years of experience studying non-alcoholic steatohepatitis (NASH)/non-alcoholic fatty liver disease (NAFLD), SMC has created the world’s first preclinical model with a type 2 diabetic ...

Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH) are the most common causes of chronic liver disease in industrialized countries. NAFLD has ...

NAFLD comprises a pathological spectrum characterized by fat accumulation within the liver known as simple steatosis, or "non-NASH NAFLD," and/or in combination with varying degrees of ...

NASH发病率明显增加，潜在市场空间巨大。非酒精性脂肪性肝病（NAFLD）是由于营养过剩和胰岛素抵抗引起的慢性进展性肝病，通常是患 者代谢问题的 ...

Belly fat, constant fatigue, pain below the right rib cage, unexplained acne or hair loss, and nausea are potential signs of ...

One of these is non-alcoholic steatohepatitis, or NASH, the fatty liver disease that affects millions of people and which is poised to be one of pharma’s next big growth areas. Novartis ramped ...

At the moment, Madrigal Pharmaceuticals seems to be in the lead to bring a NASH drug to market, after its daily oral drug resmetirom met primary and secondary objectives in a phase 3 NAFLD trial ...

Earlier this year, the United States Food and Drug Administration (FDA) approved the first and only fatty liver disease drug to be used by adults with non-alcoholic steatohepatitis (NASH).

Peptidomics offered new diagnostic insights into the underlying processes of metabolic dyfunction-associated steatotic liver ...

Madrigal Pharmaceuticals (MDGL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yasmeen ...

If you’re quietly thinking that fatty liver disease, which causes the liver ... condition called non-alcoholic steatohepatitis, or NASH, which is a leading cause of liver cancer, cirrhosis ...